Form 4: Biogen Executive Adam Keeney Reports Stock Transactions

Adam Keeney, Head of Corporate Development at Biogen, reports acquisition and disposal of common stock and restricted stock units.

Summary

• On February 7, 2025, Adam Keeney, Head of Corporate Development at Biogen, reported transactions involving Biogen's common stock and restricted stock units.
• Keeney acquired 1,801 shares of common stock upon the vesting of restricted stock units.
• Keeney disposed of 563 shares of common stock at a price of $141.35.
• Following these transactions, Keeney directly owns 1,900 shares of Biogen common stock.
• Keeney also reports ownership of 3,604 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect a broader trend in the pharmaceutical industry but rather individual investment decisions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The transactions reported are typical for executives who receive stock options or restricted stock units as part of their compensation packages.
• Similar filings can be observed for executives at comparable companies like Amgen (AMGN) and Gilead Sciences (GILD).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates

Keywords

Biogen, BIIB, Form 4, Adam Keeney, Stock Transaction, Restricted Stock Units, Corporate Development, Beneficial Ownership